Key features and details
- Expression system: Baculovirus infected Sf9 cells
- Active: Yes
- Tags: GST tag N-Terminus
- Suitable for: SDS-PAGE, Functional Studies
Product nameRecombinant human FRK protein
Specific Activity: 997 nmol/min/mg.
Expression systemBaculovirus infected Sf9 cells
Protein lengthProtein fragment
Predicted molecular weight60 kDa
Amino acids208 to 505
TagsGST tag N-Terminus
Additional sequence informationRecombinant fragment, corresponding to amino acids 208-end of Human FRK.
Our Abpromise guarantee covers the use of ab60861 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ab204877 (Poly (4:1 Glu, Tyr) peptide) can be utilized as a substrate for assessing kinase activity
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Constituents: 0.0038% EGTA, 0.00174% PMSF, 0.00385% DTT, 0.79% Tris HCl, 0.00292% EDTA, 25% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- Beta cell Src homology tyrosine kinase
FunctionPositively regulates PTEN protein stability through phosphorylation of PTEN on 'Tyr-336', which in turn prevents its ubiquitination and degradation possibly by reducing its binding to NEDD4. May function as a tumor suppressor.
Tissue specificityRestricted to cells lines derived from tissues of lymphoid, brain, breast, colon and bladder origin.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Contains 1 SH3 domain.
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab60861 has not yet been referenced specifically in any publications.